# Applied Clinical Trials Online > Applied Clinical Trials Online - Healthcare Publication - Base URL: https://www.appliedclinicaltrialsonline.com - Generated: 2026-09-29T07:13:04.286Z - Content updates: multiple times daily ## Content Access for AI Agents This site supports content negotiation for AI/LLM consumption. Request any article URL with an appropriate Accept header to receive structured content instead of HTML. **Supported content types:** - `text/markdown` — Clean Markdown with YAML frontmatter - `text/plain` — Plain text (same as Markdown) - `text/html` — Default HTML response **Example request:** ``` curl -H "Accept: text/markdown" https://www.appliedclinicaltrialsonline.com/view/article-slug ``` **YAML frontmatter schema** (returned with every Markdown response): | Field | Type | Description | |-------|------|-------------| | `title` | string | Article headline | | `description` | string | Summary/excerpt (max 300 chars) | | `url` | string | Canonical article URL | | `canonical_url` | string | Canonical URL if different from `url` | | `published` | ISO 8601 | Original publication date | | `modified` | ISO 8601 | Last modification date | | `authors` | string[] | Author display names | | `content_type` | string | Content category (e.g., "News", "Clinical") | | `categories` | string[] | Taxonomy categories | | `tags` | string[] | SEO tags | | `image` | string | Featured image URL | | `publisher` | string | Publication/site name | **Discovery headers** (included on all responses): - `Link: ; rel="llms"` — RFC 8288 link to this file - `X-Llms-Txt: https://www.appliedclinicaltrialsonline.com/llms.txt` — Explicit discovery header ## Usage Policy - Robots policy: [https://www.appliedclinicaltrialsonline.com/robots.txt](https://www.appliedclinicaltrialsonline.com/robots.txt) - Cache behavior: responses are cached for ~5 minutes (max-age=300, stale-while-revalidate=329) - Rate guidance: prefer RSS and sitemap feeds over crawling individual pages - Attribution: All content © MJH Life Sciences. Include source URLs when citing. ## Content Categories - [Additional Topics](https://www.appliedclinicaltrialsonline.com/additional-topics) - [Blogs](https://www.appliedclinicaltrialsonline.com/blogs) - [Editorial Podcasts](https://www.appliedclinicaltrialsonline.com/editorial-podcasts) - [Editorial Videos](https://www.appliedclinicaltrialsonline.com/editorial-videos) - [Events](https://www.appliedclinicaltrialsonline.com/events) - [Front & Center](https://www.appliedclinicaltrialsonline.com/front-center) - [NO ADS](https://www.appliedclinicaltrialsonline.com/noads) - [News](https://www.appliedclinicaltrialsonline.com/news) - [Sponsored Podcasts](https://www.appliedclinicaltrialsonline.com/podcasts) - [Sponsored Videos](https://www.appliedclinicaltrialsonline.com/sponsored-videos) - [Topic](https://www.appliedclinicaltrialsonline.com/topic) - [Vendor Strategy & Collaboration](https://www.appliedclinicaltrialsonline.com//topic/vendor-strategy-and-collaboration) - [Video Series](https://www.appliedclinicaltrialsonline.com/video-series) - [Webcasts](https://www.appliedclinicaltrialsonline.com/webcasts) - [White Papers](https://www.appliedclinicaltrialsonline.com/whitepapers) ## Featured Content - [Quantifying the Financial Value of RBQM: Q&A with Sylviane de Viron, CluePoints, and Abigail Dirks, Tufts CSDD](https://www.appliedclinicaltrialsonline.com/view/quantifying-financial-value-rbqm-sylviane-de-viron-cluepoints-abigail-dirks-tufts-csdd): In this Q&A, Sylviane de Viron of CluePoints and Abigail Dirks, MS, of Tufts CSDD discuss the findings of a collaborative study quantifying the financ... - [The Design Flaws Trial Simulations Surface That Traditional Planning Misses](https://www.appliedclinicaltrialsonline.com/view/design-flaws-trial-simulations-surface-traditional-planning-misses): In this video interview, Claire Riches, VP of clinical solutions at Citeline, walks through the categories of hidden protocol risk that AI-driven simu... - [ACT Brief: AI Expands Endpoint Options, CRO Oversight Documentation, and Kidney Cancer Approval](https://www.appliedclinicaltrialsonline.com/view/ai-expands-endpoint-options-cro-oversight-documentation-kidney-cancer-approval): In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work oft... - [Sponsor Oversight in an Outsourced Trial: What Good Looks Like and How to Evidence It](https://www.appliedclinicaltrialsonline.com/view/sponsor-oversight-outsourced-trial-what-good-looks-like-how-to-evidence): Sponsor oversight of outsourced CRO work is often robust in practice but fails inspection because oversight decisions are fragmented across systems an... - [How to recruit specialty volunteer populations for early-phase clinical research: 5 things to ask when choosing a CRO partner](https://www.appliedclinicaltrialsonline.com/view/how-to-recruit-specialty-volunteer-populations-for-early-phase-clinical-research-5-things-to-ask-when-choosing-a-cro-partner): In early development, effective volunteer recruitment is critical for building a robust package of clinic trial data, ensuring scientific validity, co... - [How AI Is Changing Endpoint Selection Before a Trial Even Starts](https://www.appliedclinicaltrialsonline.com/view/how-ai-changing-endpoint-selection-before-trial-even-starts): In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains how AI is expanding endpoint selection beyond the bounded exper... - [ACT Brief: Patient-Site Trust Barriers, Rare Disease Evidence Without Registry, and RWD Enrollment Accuracy](https://www.appliedclinicaltrialsonline.com/view/patient-site-trust-barriers-rare-disease-evidence-registry-rwd-enrollment-accuracy): In today's ACT Brief, we examine what patient-site relationships need beyond easier technology, how to build defensible rare disease evidence from scr... - [When There’s No Registry: Building Rare Disease Evidence That Supports Regulatory Scrutiny](https://www.appliedclinicaltrialsonline.com/view/no-registry-building-rare-disease-evidence-supports-regulatory-scrutiny): In rare disease drug development where no registry or natural history dataset exists, real-world evidence quality depends on treating evidence enginee... - [Trust, Technology, and the Patient-Site Relationship: Q&A with Andrea Valente, uMotif](https://www.appliedclinicaltrialsonline.com/view/trust-technology-patient-site-relationship-andrea-valente-umotif): In this Q&A, Andrea Valente, CEO of uMotif, discusses what it takes to build genuine trust between patients and sites, why making technology easier to... - [ACT Brief: Data Provenance and Device Strategy, Cell-Gene Therapy Site Readiness, and Data Harmonization Bottleneck](https://www.appliedclinicaltrialsonline.com/view/data-provenance-device-strategy-cell-gene-therapy-site-readiness-data-harmonization-bottleneck): In today's ACT Brief, we examine why defensible trial data depends on traceability and platform ownership, what CGT site readiness requires as therapy... ## Feeds and Indexes - [RSS Feed](https://www.appliedclinicaltrialsonline.com/rss.xml): Latest articles in XML syndication format - [Sitemap](https://www.appliedclinicaltrialsonline.com/sitemap.xml): Complete URL index for all published pages - [News Sitemap](https://www.appliedclinicaltrialsonline.com/sitemap-news.xml): Recent articles optimized for news indexing - [Authors Directory](https://www.appliedclinicaltrialsonline.com/authors): Browse all contributors and their published work